Saikat Ghosh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saikat Ghosh has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Kristofer J. Thurecht
The University of Queensland
10 shared publications - Nicholas L. Fletcher
University of Queensland
9 shared publications - Zachary H. Houston
Centre for Advanced Imaging and Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia
6 shared publications - Pie Huda
The University of Queensland
4 shared publications - Biao Sun
Queensland Brain Institute
3 shared publications - Brian Wan-Chi Tse
Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, Australia
3 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5879-5890
Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer
The application of antibody-drug conjugate (ADC) therapies in advanced bladder cancers may be improved through non-invasive molecular imaging and therapy with targeted radiation. Enfortumab and Sacituzumab, the antibody components for the ADCs PADCEV (Nectin-4 targeting) and TRODELVY (TROP2 targeting), were developed as ImmunoPET and radioimmunotherapeutic modalities in a HT1376 xenograft model of advanced bladder cancer. Both immuno-PET agents displayed distinct tumor uptake in vivo, with Sacituzumab showing higher accumulation (% ID/g) compared to Enfortumab, reflecting the higher TROP2 expression in this tumor model over Nectin-4. Further, both [177Lu]Lu-DOTA-Enfortumab and [177Lu]Lu-DOTA-Sacituzumab were effective in reducing the growth of tumors in vivo. The repurposing of well-validated ADC antibodies as theranostic radiopharmaceuticals is a promising approach for alternative or adjuvant therapies.
- 7 October 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5879-5890
Open AccessRepurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer
The application of antibody-drug conjugate (ADC) therapies in advanced bladder cancers may be improved through non-invasive molecular imaging and therapy with targeted radiation. Enfortumab and Sacituzumab, the antibody components for the ADCs PADCEV (Nectin-4 targeting) and TRODELVY (TROP2 targeting), were developed as ImmunoPET and radioimmunotherapeutic modalities in a HT1376 xenograft model of advanced bladder cancer. Both immuno-PET agents displayed distinct tumor uptake in vivo, with Sacituzumab showing higher accumulation (% ID/g) compared to Enfortumab, reflecting the higher TROP2 expression in this tumor model over Nectin-4. Further, both [177Lu]Lu-DOTA-Enfortumab and [177Lu]Lu-DOTA-Sacituzumab were effective in reducing the growth of tumors in vivo. The repurposing of well-validated ADC antibodies as theranostic radiopharmaceuticals is a promising approach for alternative or adjuvant therapies.
- 30 January 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (2) , 1280-1288
Multiplexing Label-Free Polymeric Nanocarriers via Antipolymer Antibodies
Recent examples of immune responses directed against the synthetic polymer poly(ethylene glycol) (PEG) have led to the development of biocompatible polymers, which are viewed as promising candidates to act as surrogate materials for use in biological applications, such as hydrophilic poly(2-oxazoline)s (POx). Despite this, the characterization of critical aspects of the immune response against these emerging materials is sparse, in part because no known monoclonal antibodies (mAbs) against this family of synthetic material have been reported. To advance the understanding of such responses, we report the successful isolation and characterization of hybridoma-derived mAbs with excellent specificity for different POx species and notable selectivity for highly branched polymer architectures over linear systems. In conjunction with established mAbs targeted against PEG, we show that these antibodies can be employed for sensitive in vivo multiplex-detection of label-free polymer therapeutics based on the specificity of the polymer-antibody binding. This approach enables scalable therapeutic drug monitoring of multiple polymer therapeutics within a single animal, simultaneously.
- 30 January 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (2) , 1280-1288
Multiplexing Label-Free Polymeric Nanocarriers via Antipolymer Antibodies
Recent examples of immune responses directed against the synthetic polymer poly(ethylene glycol) (PEG) have led to the development of biocompatible polymers, which are viewed as promising candidates to act as surrogate materials for use in biological applications, such as hydrophilic poly(2-oxazoline)s (POx). Despite this, the characterization of critical aspects of the immune response against these emerging materials is sparse, in part because no known monoclonal antibodies (mAbs) against this family of synthetic material have been reported. To advance the understanding of such responses, we report the successful isolation and characterization of hybridoma-derived mAbs with excellent specificity for different POx species and notable selectivity for highly branched polymer architectures over linear systems. In conjunction with established mAbs targeted against PEG, we show that these antibodies can be employed for sensitive in vivo multiplex-detection of label-free polymer therapeutics based on the specificity of the polymer-antibody binding. This approach enables scalable therapeutic drug monitoring of multiple polymer therapeutics within a single animal, simultaneously.
- 27 January 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (8) , 1504-1519
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers
Purpose: Receptor CUB domain–containing protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer. Experimental Design: CDCP1 expression was assessed immunohistochemically in tumors from 423 patients [119 triple-negative breast cancer (TNBC); 75 HER2+; and 229 ER+/HER2−, including 228 primary tumors and 229 lymph node and 47 distant metastases). Cell cytotoxicity induced in vitro by a CDCP1-targeting antibody-drug conjugate (ADC), consisting of the human/mouse chimeric antibody ch10D7 and the microtubule disruptor monomethyl auristatin E (MMAE), was quantified, including in combination with HER-targeting ADC trastuzumab emtansine (T-DM1). Detection of CDCP1-expressing primary and metastatic xenografts in mice was examined by PET–CT imaging using zirconium-89–labeled ch10D7. The impact of ch10D7-MMAE on tumor burden and survival in vivo, including in combination with T-DM1, was quantified in cell line and patient-derived xenograft mouse models. Results: CDCP1 is expressed predominantly on the surface of malignant cells of 70% of TNBC, 80% of HER2+ tumors, and increases in ER+/HER2− tumors from 44.9% in primary tumors to 56.4% in lymph node metastases and 74.3% in distant metastases. PET-CT imaging with zirconium-89–labeled ch10D7 is effective for the detection of primary and metastatic CDCP1-expressing TNBC in mice. ADC ch10D7-MMAE kills CDCP1-expressing cells in vitro and controls primary and metastatic TNBC xenografts in mice, conferring significant survival advantages over chemotherapy. It compares favorably to T-DM1 in vivo, and ch10D7-MMAE combined with T-DM1 showed the most potent efficacy, markedly reducing tumor burden of CDCP1+/HER2+ xenografts and prolonging mouse survival, compared with T-DM1 or ch10D7. Conclusions: CDCP1-directed molecular imaging has the potential to identify aggressive breast cancers for CDCP1-targeted treatment.
- 27 January 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (8) , 1504-1519
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers
Purpose: Receptor CUB domain–containing protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer. Experimental Design: CDCP1 expression was assessed immunohistochemically in tumors from 423 patients [119 triple-negative breast cancer (TNBC); 75 HER2+; and 229 ER+/HER2−, including 228 primary tumors and 229 lymph node and 47 distant metastases). Cell cytotoxicity induced in vitro by a CDCP1-targeting antibody-drug conjugate (ADC), consisting of the human/mouse chimeric antibody ch10D7 and the microtubule disruptor monomethyl auristatin E (MMAE), was quantified, including in combination with HER-targeting ADC trastuzumab emtansine (T-DM1). Detection of CDCP1-expressing primary and metastatic xenografts in mice was examined by PET–CT imaging using zirconium-89–labeled ch10D7. The impact of ch10D7-MMAE on tumor burden and survival in vivo, including in combination with T-DM1, was quantified in cell line and patient-derived xenograft mouse models. Results: CDCP1 is expressed predominantly on the surface of malignant cells of 70% of TNBC, 80% of HER2+ tumors, and increases in ER+/HER2− tumors from 44.9% in primary tumors to 56.4% in lymph node metastases and 74.3% in distant metastases. PET-CT imaging with zirconium-89–labeled ch10D7 is effective for the detection of primary and metastatic CDCP1-expressing TNBC in mice. ADC ch10D7-MMAE kills CDCP1-expressing cells in vitro and controls primary and metastatic TNBC xenografts in mice, conferring significant survival advantages over chemotherapy. It compares favorably to T-DM1 in vivo, and ch10D7-MMAE combined with T-DM1 showed the most potent efficacy, markedly reducing tumor burden of CDCP1+/HER2+ xenografts and prolonging mouse survival, compared with T-DM1 or ch10D7. Conclusions: CDCP1-directed molecular imaging has the potential to identify aggressive breast cancers for CDCP1-targeted treatment.
- Open Access
- 3 June 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (30) , 11748-11760
A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements
Covalent DFOB-DOTA dual chelator (‘D2’) binds 89 Zr (DFOB) and 177 Lu (DOTA) regio-selectively enabling 89 Zr– 177 Lu pairing as a novel cancer-targeting theranostic.
- 3 June 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (30) , 11748-11760
Open AccessA first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements
Covalent DFOB-DOTA dual chelator (‘D2’) binds 89 Zr (DFOB) and 177 Lu (DOTA) regio-selectively enabling 89 Zr– 177 Lu pairing as a novel cancer-targeting theranostic.
- 7 December 2023
- Published by University of Queensland Library
Novel antibody theranostics for oncology
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 7 December 2023
- Published by University of Queensland Library
Novel antibody theranostics for oncology
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- Open Access
- 23 May 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (6) , 3073-3087
RAFT Polymer–Antibody Conjugation: Squaramide Ester Chemistry Leads to Conjugates with a Therapeutic Anti-EGFR Antibody with Full Retention of Activity and Increased Tumor Uptake In Vivo
Covalent conjugation of a biologically stable polymerto a therapeuticprotein, e.g., an antibody, holds many benefits such as prolongedplasma exposure of the protein and improved tumor uptake. Generationof defined conjugates is advantageous in many applications, and arange of site-selective conjugation methods have been reported. Manycurrent coupling methods lead to dispersity in coupling efficiencieswith subsequent conjugates of less-well-defined structure, which impactsreproducibility of manufacture and ultimately may impact successfultranslation to treat or image diseases. We explored designing stable,reactive groups for polymer conjugation reactions that would leadto conjugates through the simplest and most abundant residue on mostproteins, the lysine residue, yielding conjugates in high purity anddemonstrating retention of mAb efficacy through surface plasmon resonance(SPR), cell targeting, and in vivo tumor targeting.We utilized squaric acid diesters as coupling agents for selectiveamidation of lysine residues and were able to selectively conjugateone, or two, high-molecular-weight polymers to a therapeutically relevantantibody, 528mAb, that subsequently retained full binding specificity.Water-soluble copolymers of N-(2-hydroxypropyl) methacrylamide(HPMA) and N-isopropylacrylamide (NIPAM) were preparedby Reversible Addition-Fragmentation chain-Transfer (RAFT)polymerization and we demonstrated that a dual-dye-labeled antibody-RAFTconjugate (528mAb-RAFT) exhibited effective tumor targeting in modelbreast cancer xenografts in mice. The combination of the precise andselective squaric acid ester conjugation method, with the use of RAFTpolymers, leads to a promising strategic partnership for improvedtherapeutic protein-polymer conjugates having a very-well-definedstructure.
- 23 May 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (6) , 3073-3087
Open AccessRAFT Polymer–Antibody Conjugation: Squaramide Ester Chemistry Leads to Conjugates with a Therapeutic Anti-EGFR Antibody with Full Retention of Activity and Increased Tumor Uptake In Vivo
Covalent conjugation of a biologically stable polymerto a therapeuticprotein, e.g., an antibody, holds many benefits such as prolongedplasma exposure of the protein and improved tumor uptake. Generationof defined conjugates is advantageous in many applications, and arange of site-selective conjugation methods have been reported. Manycurrent coupling methods lead to dispersity in coupling efficiencieswith subsequent conjugates of less-well-defined structure, which impactsreproducibility of manufacture and ultimately may impact successfultranslation to treat or image diseases. We explored designing stable,reactive groups for polymer conjugation reactions that would leadto conjugates through the simplest and most abundant residue on mostproteins, the lysine residue, yielding conjugates in high purity anddemonstrating retention of mAb efficacy through surface plasmon resonance(SPR), cell targeting, and in vivo tumor targeting.We utilized squaric acid diesters as coupling agents for selectiveamidation of lysine residues and were able to selectively conjugateone, or two, high-molecular-weight polymers to a therapeutically relevantantibody, 528mAb, that subsequently retained full binding specificity.Water-soluble copolymers of N-(2-hydroxypropyl) methacrylamide(HPMA) and N-isopropylacrylamide (NIPAM) were preparedby Reversible Addition-Fragmentation chain-Transfer (RAFT)polymerization and we demonstrated that a dual-dye-labeled antibody-RAFTconjugate (528mAb-RAFT) exhibited effective tumor targeting in modelbreast cancer xenografts in mice. The combination of the precise andselective squaric acid ester conjugation method, with the use of RAFTpolymers, leads to a promising strategic partnership for improvedtherapeutic protein-polymer conjugates having a very-well-definedstructure.
- 5 January 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (3) , 1549-1563
Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma
Glioblastoma (GBM) is the most aggressive form of primary brain cancer, accounting for about 85% of all primary central nervous system (CNS) tumors. With standard treatment strategies like surgery, radiation, and chemotherapy, the median survival time of patients with GBM is only 12-15 months from diagnosis. The poor prognosis of GBM is due to a very high tumor recurrence rate following initial treatment, indicating a dire need for improved diagnostic and therapeutic alternatives for this disease. Antibody-based immunotheranostics holds great promise in treating GBM, combining the theranostic applications of radioisotopes and target-specificity of antibodies. In this study, we developed and validated antibody-based positron emission tomography (PET) tracers targeting the heparan sulfate proteoglycan, glypican-1 (GPC-1), for noninvasive detection of disease using diagnostic molecular imaging. GPC-1 is overexpressed in multiple solid tumor types, including GBM, and is a promising biomarker for novel immunotheranostics. Here, we investigate zirconium-89 (89Zr)-conjugated Miltuximab (a clinical stage anti-GPC-1 monoclonal antibody developed by GlyTherix, Ltd.) and engineered fragments for their potential as immuno-PET tracers to detect GPC-1positive GBM tumors in preclinical models. We explore the effects of molecular size, avidity, and Fc-domain on the pharmacokinetics and biodistribution in vivo, by comparing in parallel the full-length antibody (Miltuximab), Fab'2, Fab, and single-chain variable fragment (scFv) formats. High radiolabeling efficiency (>95%) was demonstrated by all the formats and the stability post-radiolabeling was higher for larger constructs of Miltuximab and the Fab. Receptor-mediated internalization of all 89Zr-labeled formats was observed in a human GBM cell line in vitro, while full-length Miltuximab demonstrated the highest tumor retention (5.7 ± 0.94% ID/g, day-9 postinjection (p.i.)) and overall better tumor-to-background ratios than the smaller Fc-less formats. Results from in vivo PET image quantification and ex vivo scintillation counting were highly correlated. Altogether, 89Zr-DFO-Miltuximab appears to be an effective immuno-PET imaging agent for detecting GPC-1positive tumors such as GBM and the current results support utility of the Fc containing whole mAb format over smaller antibody fragments for this target.
- 5 January 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (3) , 1549-1563
Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma
Glioblastoma (GBM) is the most aggressive form of primary brain cancer, accounting for about 85% of all primary central nervous system (CNS) tumors. With standard treatment strategies like surgery, radiation, and chemotherapy, the median survival time of patients with GBM is only 12-15 months from diagnosis. The poor prognosis of GBM is due to a very high tumor recurrence rate following initial treatment, indicating a dire need for improved diagnostic and therapeutic alternatives for this disease. Antibody-based immunotheranostics holds great promise in treating GBM, combining the theranostic applications of radioisotopes and target-specificity of antibodies. In this study, we developed and validated antibody-based positron emission tomography (PET) tracers targeting the heparan sulfate proteoglycan, glypican-1 (GPC-1), for noninvasive detection of disease using diagnostic molecular imaging. GPC-1 is overexpressed in multiple solid tumor types, including GBM, and is a promising biomarker for novel immunotheranostics. Here, we investigate zirconium-89 (89Zr)-conjugated Miltuximab (a clinical stage anti-GPC-1 monoclonal antibody developed by GlyTherix, Ltd.) and engineered fragments for their potential as immuno-PET tracers to detect GPC-1positive GBM tumors in preclinical models. We explore the effects of molecular size, avidity, and Fc-domain on the pharmacokinetics and biodistribution in vivo, by comparing in parallel the full-length antibody (Miltuximab), Fab'2, Fab, and single-chain variable fragment (scFv) formats. High radiolabeling efficiency (>95%) was demonstrated by all the formats and the stability post-radiolabeling was higher for larger constructs of Miltuximab and the Fab. Receptor-mediated internalization of all 89Zr-labeled formats was observed in a human GBM cell line in vitro, while full-length Miltuximab demonstrated the highest tumor retention (5.7 ± 0.94% ID/g, day-9 postinjection (p.i.)) and overall better tumor-to-background ratios than the smaller Fc-less formats. Results from in vivo PET image quantification and ex vivo scintillation counting were highly correlated. Altogether, 89Zr-DFO-Miltuximab appears to be an effective immuno-PET imaging agent for detecting GPC-1positive tumors such as GBM and the current results support utility of the Fc containing whole mAb format over smaller antibody fragments for this target.
- 21 June 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (57) , 7912-7915
Pre-targeting of polymeric nanomaterials to balance tumour accumulation and clearance
Pre-targeting of bispecific antibodies is probed to enhance tumour retention while limiting clearance of administered multifunctional branched PEGylated nanomedicines. The temporal influence of pre-targeting on polymer interaction with tumour cells and tissue is explored using in vitro assays through to preclinical validation.
- 21 June 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (57) , 7912-7915
Pre-targeting of polymeric nanomaterials to balance tumour accumulation and clearance
Pre-targeting of bispecific antibodies is probed to enhance tumour retention while limiting clearance of administered multifunctional branched PEGylated nanomedicines. The temporal influence of pre-targeting on polymer interaction with tumour cells and tissue is explored using in vitro assays through to preclinical validation.